Daily Morning Note – 28 July 2020


Gold soared to a record high on Monday as investors rushed into the safe-haven commodity on concerns about heightened China-US tensions, spiking virus infections and a lack of progress on a new stimulus bill in Washington.

“Always a sign of trouble, gold continued its red hot streak on Monday, the safe haven commodity looking mighty attractive after another troubling weekend of Covid-19 and US-China headlines,” said Spreadex analyst Connor Campbell.

Dollar weakness was a big factor behind gold’s takeoff, analysts said, as the greenback continued its retreat against the euro and other major currencies.

The fall in the US currency comes amid expectations that the Federal Reserve will keep interest rates lower for longer and that the economy could underperform those in other regions due to the coronavirus.


Coordinators of a global coronavirus vaccines funding scheme are looking at a wide range of potential prices for Covid-19 shots, with a reported US$40 per dose price tag the “highest number” in that range, one of the co-leads of the project said on Monday. Seth Berkley, chief executive of the GAVI vaccine alliance, which is co-leading the COVAX facility designed to ensure fair global access to Covid-19 shots, said the facility had no specific target price and would also seek to negotiate tiered pricing for richer and poorer countries.

Wells Fargo & Co filed documents to register its own exchange-traded funds on Monday, making it the latest asset manager to enter the quickly growing industry. If approved, the San Francisco-based bank will be able to issue its own ETFs. Banking giants JPMorgan Chase & Co and Goldman Sachs Group Inc already have their own funds.

Tech shares led Wall Street stocks higher on Monday ahead of major economic news events, including a high-stakes congressional hearing with the heads of Amazon, Apple and other giants.

Stamford Tyres on Monday posted a net loss of S$4 million for FY20, reversing from a humble profit of S$474,000 a year ago. This was due to a one-time expense relating to the closure of a loss-making operation in Australia in Q2 FY20, as well as higher allowance for doubtful receivables as a result of delayed and non-payment of trade receivables due from customers because of Covid-19 (among other reasons); the various government-imposed lockdowns in its key markets such as Malaysia and Thailand were also a factor.

Sing Investments & Finance on Monday posted a 22.2 per cent decline in net profit to S$3.9 million for its second quarter ended June 30. This was due to the additional general allowances provided in view of the severe impact of the Covid-19 pandemic on the macroeconomic situation and outlook, it said.

Mapletree North Asia Commercial Trust on Monday posted a 10.7 per cent drop in its gross revenue to S$93.7 million. Its net property income declined 19.5 per cent to S$68.5 million for its first quarter ended June 30. The decline was mainly due to rental reliefs granted to its tenants and a lower average retail rental rate at its Festival Walk property in Hong Kong, as a result of the Covid-19 situation since early 2020, as well as a lower average occupancy at Gateway Plaza, its office building in Chaoyang District in Beijing.

GL Limited on Monday said it is expected to report a net loss for FY2020, primarily due to Covid-19 as well as lower oil prices. It said that the pandemic has resulted in widespread international travel restrictions and severely disrupted the group’s United Kingdom hospitality business led by its wholly-owned subsidiary, GLH Hotels Limited.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR


Mapletree Logistics Trust

Analyst: Chua Wei Ren

Recommended Action: Technical SELL

Mapletree Logistics Trust (SGX: M44U) enjoyed an impressive rally since our report on 17th June. Falling short of our target price of $2.25, we are expecting a correction after the recent technical.

Riverstone Holdings Ltd

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Riverstone Holdings Ltd (SGX: AP4) Strong upside is set to continue again based on the recent technical.

>> Read more technical reports


UG Healthcare Corp. – Never say never to blue skies

Recommendation: BUY (Initiation), Last Done: S$1.75

Target Price: S$2.70, Analyst: Paul Chew

– Pandemic has resulted in spot prices for gloves ballooning 5-fold. Order lead times have been stretched from one month to a year. Supply shortfall to continue until 2021.

– With its own branded gloves and distribution network, UG Healthcare should be able to monetize a larger share of supply-chain profits, starting from manufacturing to distribution

– Initiate coverage with BUY recommendation and target price of S$2.70. Valued at 15x FY21e PE, a 40% historical discount to peer on account of its smaller scale and size.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here


Webinar Of The Week

Market Outlook: Market Outlook: SG Banking Monthly, SG Bonds Weekly and SG Strategy 3Q20 (with stock picks)

Date: 06 July 2020

For more on Market Outlook

Phillip Research in 3 minutes: #25 – Prime US REIT; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com